• EverythingALS Taps ‘Power in the Crowd’ to Revamp Research Norms

    Jan 07 | Diagnostics World News | After less than three years of collecting voice samples from individuals with amyotrophic lateral sclerosis, and a control group of healthy volunteers, the Peter Cohen Foundation awaits approval from the Food and Drug Administration of its algorithm as a secondary biomarker for tracking the progression of the devastating neurological disease. The drug development tool, a “listener effort” prediction model, will be used in a multitude of clinical trials as soon as the first quarter of 2026. More

  • Trendspotting: Precision Diagnostics, Artificial Intelligence, Data Management, Collection

    Jan 06 | Diagnostics World News | To kick off 2026, we spoke with industry experts and leaders in the Diagnostics World community about what they expect and look forward to in the new year. Here are the full trends and predictions, including more on AI, data management and collection, precision diagnostics, new testing, and more. More

  • Top Stories of 2025: AI, Cancer Detection, Women’s Health

    Dec 29 | Diagnostics World News | Diagnostics is gaining growing traction within several companies not historically diagnostics-focused, and it is the subject of a fair amount of AI investment as well. NVIDIA’s partnerships with diagnostics companies came up in more than one top story of the year, and AI’s role for image processing came up in others. Even earlier multi-cancer early detection tests were notable and the growing trend in women’s health was reflected in attention to endometriosis diagnosis. More

  • Follow the Money: First-in-Class Circular RNA Platform for Alzheimer’s, Novel Wireless Heart Monitor, Non-Surgical Brain Monitoring

    Dec 23 | Diagnostics World News | Circular Genomics will accelerate the clinical development and commercialization of their circRNA biomarker platform for the early detection of Alzheimer's disease; Wearlinq introduces eWave, the first continuous, multi-lead (6-lead) ECG in a small, wireless form factor; Subsense is building a bidirectional BCI platform designed to record and modulate brain activity without surgical implants; and more. More

  • Singapore-MIT Alliance for Research and Technology’s New Project, Cleveland Diagnostics In Vivo Kit, Roche Test Receives FDA Clearance

    Dec 22 | Diagnostics World News | The Singapore-MIT Alliance for Research and Technology launches a new collaborative research project; Cleveland Diagnostics receives FDA approval of their IsoPSA in vitro diagnostic kit; Roche announces that its first point-of-care test for the detection of Bordetella infections has been granted FDA 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 waiver; and more. More

  • New Gut Peptide Discovery Opens Door to Allergy Treatment

    Dec 18 | Diagnostics World News | Researchers have identified a previously overlooked mechanism controlling allergic reactions in the gut, potentially paving the way for novel treatments for conditions ranging from food allergies to irritable bowel syndrome. More

  • AI Enabling Clinical-Grade, Wearable-Based Sleep Tracking

    Dec 16 | Diagnostics World News | Good sleep patterns impact many aspects of the broader health status of individuals, but the measurement of slumber quality tends to fall at the extremes of either simplistic sleep logs or cumbersome in-patient sleep studies, or polysomnography. A new sleep-staging framework driven by artificial intelligence and an associated Apple Watch app known as BIDSleep is designed to bridge that gap by turning a smartwatch into a sleep-staging device that can distinguish between light, deep, and rapid eye movement sleep. More

  • Illumina Invests, Partners with MyOme AI-integrated Risk Models

    Dec 11 | Diagnostics World News | Illumina today announced an investment and collaboration into MyOme, a genomics and risk modeling company. The collaboration and investment will help advance MyOme’s Proactive Health (MPH) Trial—a clinical trial seeking to quantify the cost savings and improved patient outcomes for whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs)—and help expand MyOme’s suite of proactive health and rare disease diagnostic tests. Neither financial details nor milestones of the investment were disclosed. More

  • Precision Diagnostics Emerging from Psychedelic Psychiatry

    Dec 10 | Diagnostics World News | Thanks to promising developments in psychedelic and dissociative compounds, treatments for depression are likely to significantly change in the next 10 years. However, psychedelics also come with their own set of complications and side effects, such as disconnection from oneself and one’s surroundings and cardiovascular changes. More

  • Oxford Nanopore Chooses New CEO With Diagnostics Expertise

    Dec 08 | Diagnostics World News | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more